Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer

Дата публикации: 16-10-2026 15:00:13

For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase Ib trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
2	Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC	0	15	27-07-2026
3	Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC	0	9.27	17-09-2026
4	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
5	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
6	Redesigned lung cancer drug matches tumor control with fewer off-target interactions	0	9.72	24-07-2026
7	Precision therapy for metastatic prostate cancer improves survival	2	7	20-08-2024
8	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
9	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 10.75. Источник: medicalxpress.com.